Watson Pharmaceuticals Inc Completes Acquisition Of Actavis Group
Watson Pharmaceuticals Inc announced that it has completed the acquisition of the Actavis Group for EUR4.25 billion. Watson funded the transaction through a combination of $1.8 billion in term loan borrowings and the issuance of $3.9 billion in senior unsecured notes.
Latest Developments for Actavis Inc
Latest Key Developments in Pharmaceuticals
- Grifols SA’s Study Demonstrates Higher Dose Of PROLASTIN-C Increases Levels Of Alpha1-PI To Within Normal Range In Patients With AAT Deficiency-DJ
- Protalex Inc Announces Positive Interim Review of Phase 1b Trial Of PRTX-100 in Rheumatoid Arthritis By Independent Data Safety Monitoring Committee
- Pfizer Inc Announces Plan For Split-Off Of Zoetis Inc
- Salix Pharmaceuticals Ltd Announces Results For Budesonide Foam In Treatment Of Active Mild To Moderate Ulcerative Proctitis Or Ulcerative Proctosigmoiditis In Two Pivotal Phase 3 Studies
- Share this
- Link this
- Digg this
Follow Reuters